Arturo J Martí-CarvajalIván SolàPedro I. Marti-Carvajal2026-03-222026-03-22201210.1002/14651858.cd006007.pub3https://doi.org/10.1002/14651858.cd006007.pub3https://andeanlibrary.org/handle/123456789/85884Citaciones: 9No randomised clinical trials assessing the benefits and harms of antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease were identified. The benefits and harms of antifibrinolytic amino acids need to be tested in randomised clinical trials. Unless randomised clinical trials are conducted to assess the trade off between benefits and harms, we cannot recommend nor refute antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver diseases.enMedicineAntifibrinolyticCochrane LibraryClinical trialInternal medicineRandomized controlled trialLiver diseaseTranexamic acidIntensive care medicinereview